Tg Therapeutics: B. Riley Securities Raises Buy Rating, PT to $55 from $53.

Tg Therapeutics: B. Riley Securities Raises Buy Rating, PT to $55 from $53.

B. Riley Securities has increased its price target on TG Therapeutics, Inc. from $53 to $55, while maintaining a "buy" rating. The upgrade reflects the investment bank's confidence in the biopharmaceutical company's pipeline and market potential B. Riley Raises Price Target on TG Therapeutics to $55 From $53, Keeps Buy Rating^[1].

TG Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell diseases. Its pipeline includes Ublituximab, an anti-CD20 monoclonal antibody, TG-1701, a BTK inhibitor, and TG-1801, a bispecific CD47 and CD19 antibody. These therapies target various B-cell malignancies and multiple sclerosis B. Riley Raises Price Target on TG Therapeutics to $55 From $53, Keeps Buy Rating^[1].

The company's latest product, BRIUMVI, is an anti-CD20 monoclonal antibody for the treatment of relapsing-remitting multiple sclerosis (RRMS), clinically isolated syndrome, and active secondary progressive disease. TG-1701 is a novel, orally available BTK inhibitor that exhibits selectivity to BTK in in vitro kinase screening, while TG-1801 is a bispecific antibody targeting both CD19 and CD47 B. Riley Raises Price Target on TG Therapeutics to $55 From $53, Keeps Buy Rating^[1].

B. Riley Securities' analyst team believes that TG Therapeutics' robust pipeline and strategic approach to in-licensing, partnerships, and acquisitions position the company well for growth. The upgrade in price target reflects the analyst's positive outlook on the company's prospects and potential for future value creation B. Riley Raises Price Target on TG Therapeutics to $55 From $53, Keeps Buy Rating^[1].